Q-omics provides the consensus-scored MIR4316 profile across patient tissues and cancer cell-line models. MIR4316 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR4316 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, MIR4316 RNA expression shows 5,550 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, and STAD as cancer lineages where MIR4316 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4316 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4316 survival associations across molecular data types. MIR4316 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4316 RNA expression–survival associations across cancer types. High MIR4316 expression shows unfavorable associations in UVM, LIHC, KICH, COAD and THCA, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR4316 RNA expression.
This table summarizes MIR4316 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4316. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4316 shows higher tumor expression in STAD, LUAD and KIRC. The STAD box plot shows higher MIR4316 RNA expression in tumor versus normal tissue (log2 FC = +0.262, t-test p = .045).
This table shows molecular features associated with MIR4316 in patient tissues and cancer cell lines. In patient samples, MIR4316 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
